Thanakit Pongpitakmetha1, Panagiotis Fotiadis1, Marco Pasi1, Gregoire Boulouis1, Li Xiong1, Andrew D Warren1, Kristin M Schwab1, Jonathan Rosand1, M Edip Gurol1, Steven M Greenberg1, Anand Viswanathan1, Andreas Charidimou2. 1. From the Hemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, Department of Neurology (T.P., P.F., M.P., G.B., L.X., A.D.W., K.M.S., J.R., M.E.G., S.M.G., A.V., A.C.), and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, and MIND Informatics, Massachusetts General Hospital Biomedical Informatics Core (J.R.), Harvard Medical School, Boston; and Department of Pharmacology, Faculty of Medicine (T.P.), Chulalongkorn University, Bangkok, Thailand. 2. From the Hemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, Department of Neurology (T.P., P.F., M.P., G.B., L.X., A.D.W., K.M.S., J.R., M.E.G., S.M.G., A.V., A.C.), and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, and MIND Informatics, Massachusetts General Hospital Biomedical Informatics Core (J.R.), Harvard Medical School, Boston; and Department of Pharmacology, Faculty of Medicine (T.P.), Chulalongkorn University, Bangkok, Thailand. andreas.charidimou.09@ucl.ac.uk.
Abstract
OBJECTIVE: To investigate the prevalence, predictors, and clinical relevance of cortical superficial siderosis (cSS) progression in cerebral amyloid angiopathy (CAA). METHODS: Consecutive patients with symptomatic CAA meeting Boston criteria in a prospective cohort underwent baseline and follow-up MRI within 1 year. cSS progression was evaluated on an ordinal scale and categorized into mild (score 1-2 = cSS extension within an already present cSS focus or appearance of 1 new cSS focus) and severe progression (score 3-4 = appearance of ≥2 new cSS foci). Binominal and ordinal multivariable logistic regression were used to determine cSS progression predictors. We investigated future lobar intracerebral hemorrhage (ICH) risk in survival analysis models. RESULTS: We included 79 patients with CAA (mean age, 69.2 years), 56 (71%) with lobar ICH at baseline. cSS progression was detected in 23 (29%) patients: 15 (19%) patients had mild and 8 (10%) severe progression. In binominal multivariable logistic regression, ICH presence (odds ratio [OR], 7.54; 95% confidence interval [CI], 1.75-53.52; p = 0.016) and baseline cSS (OR, 10.41; 95% CI, 2.84-52.83; p = 0.001) were independent predictors of cSS progression. In similar models, presence of disseminated (but not focal) cSS at baseline (OR, 5.58; 95% CI, 1.81-19.41; p = 0.004) was an independent predictor of cSS progression. Results were similar in ordinal multivariable logistic regression models. In multivariable Cox regression analysis, severe cSS progression was independently associated with increased future ICH risk (HR, 5.90; 95% CI, 1.30-26.68; p = 0.021). CONCLUSIONS: cSS evolution on MRI is common in patients with symptomatic CAA and might be a potential biomarker for assessing disease severity and future ICH risk. External validation of these findings is warranted.
OBJECTIVE: To investigate the prevalence, predictors, and clinical relevance of cortical superficial siderosis (cSS) progression in cerebral amyloid angiopathy (CAA). METHODS: Consecutive patients with symptomatic CAA meeting Boston criteria in a prospective cohort underwent baseline and follow-up MRI within 1 year. cSS progression was evaluated on an ordinal scale and categorized into mild (score 1-2 = cSS extension within an already present cSS focus or appearance of 1 new cSS focus) and severe progression (score 3-4 = appearance of ≥2 new cSS foci). Binominal and ordinal multivariable logistic regression were used to determine cSS progression predictors. We investigated future lobar intracerebral hemorrhage (ICH) risk in survival analysis models. RESULTS: We included 79 patients with CAA (mean age, 69.2 years), 56 (71%) with lobar ICH at baseline. cSS progression was detected in 23 (29%) patients: 15 (19%) patients had mild and 8 (10%) severe progression. In binominal multivariable logistic regression, ICH presence (odds ratio [OR], 7.54; 95% confidence interval [CI], 1.75-53.52; p = 0.016) and baseline cSS (OR, 10.41; 95% CI, 2.84-52.83; p = 0.001) were independent predictors of cSS progression. In similar models, presence of disseminated (but not focal) cSS at baseline (OR, 5.58; 95% CI, 1.81-19.41; p = 0.004) was an independent predictor of cSS progression. Results were similar in ordinal multivariable logistic regression models. In multivariable Cox regression analysis, severe cSS progression was independently associated with increased future ICH risk (HR, 5.90; 95% CI, 1.30-26.68; p = 0.021). CONCLUSIONS: cSS evolution on MRI is common in patients with symptomatic CAA and might be a potential biomarker for assessing disease severity and future ICH risk. External validation of these findings is warranted.
Authors: A Biffi; A Halpin; A Towfighi; A Gilson; K Busl; N Rost; E E Smith; M S Greenberg; J Rosand; A Viswanathan Journal: Neurology Date: 2010-08-24 Impact factor: 9.910
Authors: François De Guio; Eric Jouvent; Geert Jan Biessels; Sandra E Black; Carol Brayne; Christopher Chen; Charlotte Cordonnier; Frank-Eric De Leeuw; Martin Dichgans; Fergus Doubal; Marco Duering; Carole Dufouil; Emrah Duzel; Franz Fazekas; Vladimir Hachinski; M Arfan Ikram; Jennifer Linn; Paul M Matthews; Bernard Mazoyer; Vincent Mok; Bo Norrving; John T O'Brien; Leonardo Pantoni; Stefan Ropele; Perminder Sachdev; Reinhold Schmidt; Sudha Seshadri; Eric E Smith; Luciano A Sposato; Blossom Stephan; Richard H Swartz; Christophe Tzourio; Mark van Buchem; Aad van der Lugt; Robert van Oostenbrugge; Meike W Vernooij; Anand Viswanathan; David Werring; Frank Wollenweber; Joanna M Wardlaw; Hugues Chabriat Journal: J Cereb Blood Flow Metab Date: 2016-05-11 Impact factor: 6.200
Authors: Andreas Charidimou; Sergi Martinez-Ramirez; Ashkan Shoamanesh; Jamary Oliveira-Filho; Matthew Frosch; Anastasia Vashkevich; Alison Ayres; Jonathan Rosand; Mahmut Edip Gurol; Steven M Greenberg; Anand Viswanathan Journal: Neurology Date: 2015-02-25 Impact factor: 9.910
Authors: R N K Nandigam; A Viswanathan; P Delgado; M E Skehan; E E Smith; J Rosand; S M Greenberg; B C Dickerson Journal: AJNR Am J Neuroradiol Date: 2008-11-11 Impact factor: 3.825
Authors: Joanna M Wardlaw; Eric E Smith; Geert J Biessels; Charlotte Cordonnier; Franz Fazekas; Richard Frayne; Richard I Lindley; John T O'Brien; Frederik Barkhof; Oscar R Benavente; Sandra E Black; Carol Brayne; Monique Breteler; Hugues Chabriat; Charles Decarli; Frank-Erik de Leeuw; Fergus Doubal; Marco Duering; Nick C Fox; Steven Greenberg; Vladimir Hachinski; Ingo Kilimann; Vincent Mok; Robert van Oostenbrugge; Leonardo Pantoni; Oliver Speck; Blossom C M Stephan; Stefan Teipel; Anand Viswanathan; David Werring; Christopher Chen; Colin Smith; Mark van Buchem; Bo Norrving; Philip B Gorelick; Martin Dichgans Journal: Lancet Neurol Date: 2013-08 Impact factor: 44.182
Authors: Suzanne E van Dijk; Jeroen van der Grond; Jessie Lak; Annette van den Berg-Huysmans; Gerda Labadie; Gisela M Terwindt; Marieke J H Wermer; M Edip Gurol; Mark A van Buchem; Steven M Greenberg; Sanneke van Rooden Journal: Stroke Date: 2022-04-01 Impact factor: 10.170